These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 8119236)

  • 21. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
    Molnár I; Balázs C
    Acta Med Hung; 1991; 48(1-2):13-21. PubMed ID: 1813853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Graves' ophthalmopathy and uveitis after radioiodine therapy for Graves' disease in a patient with HTLV-I associated myelopathy (HAM).
    Ozawa Y; Migita M; Watanabe T; Okuda I; Takeshita A; Takagi A; Shishiba Y
    Intern Med; 1994 Sep; 33(9):564-8. PubMed ID: 8000111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etiopathogenesis of Graves' disease.
    Karasek M; Lewinski A
    Neuro Endocrinol Lett; 2003; 24(3-4):161-6. PubMed ID: 14523350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein.
    Bahn RS; Gorman CA; Johnson CM; Smith TJ
    J Clin Endocrinol Metab; 1989 Sep; 69(3):622-8. PubMed ID: 2760173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic factors in Graves' ophthalmopathy.
    Frecker M; Stenszky V; Balazs C; Kozma L; Kraszits E; Farid NR
    Clin Endocrinol (Oxf); 1986 Nov; 25(5):479-85. PubMed ID: 3113776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. More on smoking habits and Graves' ophthalmopathy.
    Bartalena L; Martino E; Marcocci C; Bogazzi F; Panicucci M; Velluzzi F; Loviselli A; Pinchera A
    J Endocrinol Invest; 1989 Nov; 12(10):733-7. PubMed ID: 2614012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA-DR associations with Graves' disease in eastern Hungary.
    Stenszky V; Kozma L; Balazs C; Farid NR
    Clin Invest Med; 1983; 6(3):181-4. PubMed ID: 6580983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic criteria for Graves' ophthalmopathy.
    Bartley GB; Gorman CA
    Am J Ophthalmol; 1995 Jun; 119(6):792-5. PubMed ID: 7785696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical presentation of Graves' ophthalmopathy.
    Wiersinga WM; Smit T; van der Gaag R; Mourits M; Koornneef L
    Ophthalmic Res; 1989; 21(2):73-82. PubMed ID: 2786616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole.
    Kung AW; Yau CC; Cheng A
    J Clin Endocrinol Metab; 1994 Aug; 79(2):542-6. PubMed ID: 7913934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carotid cavernous fistula in a patient with Graves' ophthalmopathy.
    Loré F; Polito E; Cerase A; Bracco S; Loffredo A; Pichierri P; Talidis F
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3487-90. PubMed ID: 12915622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma exchange therapy for severe Graves' ophthalmopathy.
    Glinoer D; Schrooyen M
    Horm Res; 1987; 26(1-4):184-9. PubMed ID: 3596467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy.
    Antonelli A; Saracino A; Alberti B; Canapicchi R; Cartei F; Lepri A; Laddaga M; Baschieri L
    Acta Endocrinol (Copenh); 1992 Jan; 126(1):13-23. PubMed ID: 1736548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Graves' disease and Graves' ophthalmopathy with the polymorphisms in promoter and exon 1 of cytotoxic T lymphocyte associated antigen-4 gene.
    Zhang Q; Yang YM; Lv XY
    J Zhejiang Univ Sci B; 2006 Nov; 7(11):887-91. PubMed ID: 17048303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of antibodies in Graves' ophthalmopathy].
    Molnár I; Balázs C
    Orv Hetil; 1991 Sep; 132(38):2097-100. PubMed ID: 1923482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe Graves' ophthalmopathy after retrobulbar anesthesia for cataract extraction in a patient with mild stable thyroid eye disease.
    Wai DC; Ho SC; Seah LL; Fong KS; Khoo DH
    Thyroid; 2003 Aug; 13(8):823-6. PubMed ID: 14558926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
    Molnár I; Bokk A
    Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Graves' ophthalmopathy in childhood and adolescence.
    Uretsky SH; Kennerdell JS; Gutai JP
    Arch Ophthalmol; 1980 Nov; 98(11):1963-4. PubMed ID: 6893665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.